Provectus' partnering philosophy is guided by the belief that partnerships entered into should serve the best interests of the patients, the scientific, clinical, and commercial development of our investigational therapies, and Provectus' shareholders.
Provectus is open to any reasonable partnership proposals that will accelerate bringing our medicines to market.
Provectus and POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of top-tier academic medical centers developing new pediatric cancer therapies, entered into a joint research agreement focused on pediatric applications of PV-10, an investigational oncolytic immunotherapy, as a potential treatment for childhood cancers. The program will involve collaboration with a number of NCI Cancer Centers that are part of the POETIC group including Memorial Sloan Kettering Cancer Center (MSK), Alberta Children's Hospital, and other top-tier cancer centers of excellence.
Discussions between researchers at Provectus and Pfizer led to jointly owned US patent 9,107,887 covering the use of Provectus' investigational anti-cancer drug, PV-10, in combination with systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, PD-1 and PD-L1 antibodies, along with enhancers of immune system up-regulation, such as IL-2 and interferon-gamma.
Provectus and Boehringer signed a letter of intent in July 2015 for the purpose of laying a foundation for collaboration in bringing Provectus' investigational anti-cancer drug, PV-10, to market in mainland China, Hong Kong and Taiwan.